Renub

    Global Vaccines Market, Size, Share, Forecast 2023-2028, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

    Excel: 8 Hours
    PDF: 24 Hours
    Aug 2023
    Pages: 370

    Global Vaccine Market Outlook

    Global Vaccine Market size is anticipated to reach US$ 92.32 Billion by 2028, according to Renub Research. There has been substantial progress in the availability of critical public health vaccinations during the previous two decades. New vaccinations have been developed and distributed globally, saving many lives and preventing illness. However, a thorough examination of the global vaccination business indicates significant impediments that continue to exist. Biological preparations known as vaccine give recipients active acquired immunity to infectious illnesses. They encourage the immune system to generate antibodies that will defend against upcoming infections. Vaccine prevent diseases like MMR, control contagion, eradicate smallpox, and save lives.

    The use of vaccinations in the treatment and prevention of infectious illnesses has many benefits. Immunization prevents disease spread, protecting vaccinated and unvaccinated individuals. Studies confirm vaccine' reliability, safety, and efficacy. Immunization costs less than treating preventable diseases, making it a cost-effective public health strategy.

     

    Global Vaccine Market Size, 2023-2028 (Billion US$)

     

    global-vaccines-market

     

    Note: The chart above shows dummy data and is only for illustration purposes. Please get in touch with us for the actual market size and trends.


    Global vaccine market is projected to grow at a CAGR of 8.64% between 2022 and 2028.

    Vaccine remain the most effective method for preventing prevalent infectious diseases worldwide. In the United States, the incidence of influenza fluctuates annually, with approximately 38 million cases, 480,000 hospitalizations, and 34,000 deaths reported in 2022. Normally, 10% to 15% of the population is affected by the flu, but more severe seasons can lead to higher infection rates.

    Vaccine technology has evolved, driven by the need for faster response and improved efficacy. Genetic engineering has enabled the development of new vaccine, including attenuated virus vaccine. Rapid detection and high concentration levels are achieved through advanced technologies. Innovation focuses on challenging targets, enhanced delivery systems, synthetic candidates, genomic analysis, antigen design, and nanoparticle delivery. These advancements revolutionize vaccine development for quicker deployment and increased effectiveness. However, vaccine development is a lengthy, complex, and expensive process lasting 10-15 years, influenced by variations in materials, equipment, and regulatory requirements, restricting market growth. As a result, the value of the global vaccine market was US$ 56.16 Billion in 2022.


    Pneumococcal vaccine has a high share in the global vaccine market due to disease prevalence and emerging market demand

    Vaccine market share shows that influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, Travel & Miscellaneous, HIB, Combos, Polio, Rotavirus, and Varicella segments make up the majority of the global vaccine market.

    Pneumococcal illness is a deadly global hazard caused by Streptococcus pneumonia but can be prevented with vaccinations. Particularly pneumococcal conjugate vaccination (PCV13) for young children, they are commonly used. In areas with limited vaccine access, the demand for pneumococcal vaccine is rising. Their significant market share is driven by new discoveries, growing awareness, and improved accessibility.


    United States is expected to continue to dominate the global vaccination industry in the years to come

    By country, the global vaccine market is divided into the United States, Canada, Mexico, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World. The United States, with its robust pharmaceutical industry and leading vaccine manufacturers, including Pfizer, Merck, and Johnson & Johnson, holds a dominant position in the global vaccine market. 

    The country strong regulatory framework ensures the safety and efficacy of vaccine, fostering public trust and high coverage rates. The large and diverse population creates a substantial demand for vaccine, while supportive government policies provide financial backing for research, development, procurement, and distribution. The United States leads the world vaccination industry due to early investments in vaccine research, a strong public health system, and a supportive regulatory framework.


    Influenza vaccine lead to vaccinated people share in the global vaccine market

    Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, HIB, Combos, Polio, Rotavirus, and Varicella are among the vaccine that make up the majority of the world vaccine market by number of persons who have received them. Influenza is a deadly respiratory infection, but vaccine reduce illness risk by 40% to 60% globally, including in the US. Emerging markets exhibit a growing demand for influenza vaccine due to high prevalence and limited access to vaccine. These factors contribute to the expected high market share of influenza vaccine in the global vaccine market. The seasonal nature of influenza also aids in vaccination planning, government mandates increase vaccination rates, and increasing public awareness of the importance of influenza vaccination drives demand for these vaccine.

    Combo vaccine, which combine multiple vaccine into a single shot. Combo vaccine offer the convenience of a single shot for patients and healthcare providers while providing effective protection against a wider range of pathogens. They are generally safe, with risks of side effects similar to separate vaccine. Combo vaccine can save on administration costs and the need for multiple doses, making them more cost-effective. The growth of combo vaccine is supported by government initiatives, rising awareness of vaccination benefits, and advancements in vaccine technology, leading to improved and more accessible options for protecting against multiple diseases.


    Pediatric vaccine grow in the global vaccine market due to childhood diseases and their prevention effectiveness

    Adult and Pediatric are the types constituting the global vaccine market. Pediatric vaccinations, including MMR, prevent serious illnesses and save lives. With recommendations from health agencies like the CDC in the US, these vaccine are extensively used throughout the world. In emerging areas where there is limited access to vaccine yet a high prevalence of children's diseases, there is an increasing demand for pediatric vaccine. New pediatric vaccine, growing vaccination awareness, and improved global immunization access contribute to higher childhood immunization rates, driving the market share of pediatric vaccine.


    Global vaccine market is anticipated to continue to be dominated by Pediatric Vaccine

    Adult and pediatric are the two categories in the global vaccine market. Worldwide, pediatric vaccine are crucial in preventing prevalent childhood diseases. For instance, measles, mumps, and rubella (MMR) can have severe consequences. Pediatric vaccine have high efficacy rates, such as the 97% effectiveness of the MMR vaccine. They are widely used, and experience growing demand, particularly in emerging markets with limited vaccine access. The development of new vaccine broadens protection against childhood diseases. Increasing awareness of vaccination importance and improved vaccine accessibility contribute to their global vaccine market features and trends growth. Governments often mandate pediatric vaccine due to the higher transmission risk and impact on children's health, further emphasizing their importance.

     

    Global Vaccine Market Share, By Vaccine (Percentage)

     

    global-vaccines-market

     

    Note: The chart above shows dummy data and is only for illustration purposes. Please get in touch with us for the actual market size and trends.


    Key Players

    GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited are some of the top companies competing in the global vaccine market. Market demand, R&D, patent protection, pricing, regulatory approvals, manufacturing capabilities, and global expansion drive competition among vaccine companies to meet needs, innovate, gain exclusivity, attract customers, ensure quality, and expand market reach.

    In January 2022- In order to assess the safety, immunogenicity, and tolerability of a potential Omicron-based vaccination in adults between the ages of 18 and 55, Pfizer Inc. and BioNTech SE started a clinical trial.


    Renub Research latest report “Global Vaccine Market, Share (Influenza, HPV, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, Travel & Miscellaneous, HIB, Combos, Polio, Rotavirus, and Varicella), Country (United States, Canada, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Mexico, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World), Vaccinated People (Influenza, Cervical Cancer, Zoster, MMR, Pneumococcal, Meningococcal, Hepatitis, DTap/Tdap, HIB, Combos, Polio, Rotavirus, and Varicella), Categories (Adult, and pediatric), Companies (GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited)” provides a detailed analysis of Global Vaccine Market.


    Vaccine Market Share – Global Vaccine Market has been covered from 14 viewpoints:

    1.    Influenza
    2.    HPV
    3.    Zoster
    4.    MMR
    5.    Pneumococcal
    6.    Meningococcal
    7.    Hepatitis
    8.    DTap/Tdap
    9.    Travel & Miscellaneous
    10.    HIB
    11.    Combos
    12.    Polio
    13.    Rotavirus
    14.    Varicella


    Country – Global Vaccine Market has been covered from 21 viewpoints:

    1.    North America

    1.1    United States
    1.2    Canada

    2.    Europe

    2.1    United Kingdom
    2.2    Germany
    2.3    France
    2.4    Russia
    2.5    Italy
    2.6    Spain
    2.7    Switzerland

    3.    Asia Pacific

    3.1    India
    3.2    China
    3.3    Japan
    3.4    Australia
    3.5    South Korea

    4.    Latin America

    4.1    Mexico
    4.2    Brazil
    4.3    Argentina

    5.    Middle East & Africa

    5.1    Saudi Arabia
    5.2    UAE
    5.3    South Africa

    6.    Rest of the World


    Vaccinated People – Global Vaccine Market has been covered from 13 viewpoints:

    1.    Influenza
    2.    Cervical Cancer
    3.    Zoster
    4.    MMR
    5.    Pneumococcal
    6.    Meningococcal
    7.    Hepatitis
    8.    DTap/Tdap
    9.    HIB
    10.    Combos
    11.    Polio
    12.    Rotavirus
    13.    Varicella


    Category – Global Vaccine Market has been covered from 2 viewpoints:

    1.    Adult
    2.    Pediatric


    Company Insights:

    •    Oveview
    •    Recent Development and Initiatives
    •    Sales Analysis


    Company Analysis:

    1.    GlaxoSmithKline plc,
    2.    AstraZeneca plc, 
    3.    Sanofi Pasteur, 
    4.    Pfizer Inc.,
    5.    CSL Limited


    Report Details:

    Report Features Details
    Base Year 2022
    Historical Period 2018 - 2022
    Forecast Period 2023 - 2028
    Market US$ Billion
    Segment Covered Disease wise, Countries and Category
    Countries Covered United States, Canada, United Kingdom, Germany, France, Russia, Italy, Spain, Switzerland, India, China, Japan, Australia, South Korea, Mexico, Brazil, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World
    Companies Covered GlaxoSmithKline plc, AstraZeneca plc, Sanofi Pasteur, Pfizer Inc., and CSL Limited
    Customization Scope 20% Free Customization
    Post-Sale Analyst Support 1 Year (52 Weeks)
    Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request)

    1.    Introduction

    2.    Research Methodology

    3.    Executive Summary

    4.    Market Dynamics

    4.1    Growth Driver
    4.2    Challenges


    5.    Global Vaccines Market

    5.1    Adult Vaccines Market
    5.2    Pediatric (Infant) Vaccines Market


    6.    Global Vaccinated People

    6.1    Adult Vaccinated People
    6.2    Pediatric (Infant) Vaccinated People


    7.    Share Analysis – Global Vaccines Market & People 

    7.1    Vaccine Market Share
    7.2    By Country
    7.3    Vaccinated People Share


    8.    Categories – Global Vaccines Market & People Share

    8.1    Adult VsPediatric (Infant) Vaccines Market Share
    8.2    Adult VsPediatric (Infant) Vaccines Number Share


    9.    Disease wise – Vaccines Market and Forecast

    9.1    Influenza – Total Vaccines Market

    9.1.1    Influenza – Adult Vaccines Market
    9.1.2    Influenza – Pediatric (Infant) Vaccines Market

    9.2    Cervical Cancer (HPV) – Vaccines Market
    9.3    Zoster (Shingles) – Vaccines Market
    9.4    MMR (Measles, Mumps, and Rubella Vaccine) – Total Vaccines Market

    9.4.1    MMR – Adult Vaccines Market
    9.4.2    MMR – Pediatric (Infant) Vaccines Market

    9.5    Pneumococcal – Total Vaccines Market

    9.5.1    Pneumococcal – Adult Vaccines Market
    9.5.2    Pneumococcal – Pediatric (Infant) Vaccines Market

    9.6    Meningococcal – Total Vaccines Market

    9.6.1    Meningococcal – Adult Vaccines Market
    9.6.2    Meningococcal – Pediatric (Infant) Vaccines Market

    9.7    Hepatitis – Total Vaccines Market

    9.7.1    Hepatitis – Adult Vaccines Market
    9.7.2    Hepatitis – Pediatric (Infant) Vaccines Market

    9.8    TdaP and DTaP – Total Vaccines Market

    9.8.1    TdaP – Adult Vaccines Market
    9.8.2    DTaP – Pediatric (Infant) Vaccines Market

    9.9    Travel and Miscellaneous – Vaccines Market
    9.10    HaemophilusInfluenzae Type B (HIB) – Vaccines Market
    9.11    Combos (Combination) – Vaccines Market
    9.12    Polio – Vaccines Market
    9.13    Rotavirus – Vaccines Market
    9.14    Varicella – Vaccines Market

    9.14.1    Varicella – Adult Vaccines Market
    9.14.2    Varicella – Pediatric (Infant) Vaccines Market


    10.    Disease wise – Numbers of Vaccinated People & Forecast

    10.1    Influenza – Total Number of Vaccinated People

    10.1.1    Influenza – Number of Vaccinated Adults
    10.1.2    Influenza – Number of Vaccinated Infants

    10.2    Cervical Cancer (HPV) – Number of Vaccinated People
    10.3    Zoster (Shingles) – Number of Vaccinated People
    10.4    MMR – Total Number of Vaccinated People

    10.4.1    MMR – Number of Vaccinated Adults
    10.4.2    MMR – Number of Vaccinated Infants (Pediatric)

    10.5    Pneumococcal – Total Number of Vaccinated People

    10.5.1    Pneumococcal – Number of Vaccinated Adults
    10.5.2    Pneumococcal – Number of Vaccinated Infants

    10.6    Meningococcal – Total Number of Vaccinated People

    10.6.1    Meningococcal – Number of Vaccinated Adults
    10.6.2    Meningococcal – Number of Vaccinated Infants

    10.7    Hepatitis – Total Number of Vaccinated People

    10.7.1    Hepatitis – Number of Vaccinated Adults
    10.7.2    Hepatitis – Number of Vaccinated Infants

    10.8    TdaP and DTaP – Total Number of Vaccinated People

    10.8.1    TdaP – Number of Vaccinated Adults
    10.8.2    DTaP – Number of Vaccinated Infants

    10.9    Hib (HaemophilusInfluenzae Type B) – Number of Vaaccinated Infants
    10.10    Combos (Combination Vaccines) – Number of Vaccinated Infants
    10.11    Polio – Number of Infants Immunized and Forecast
    10.12    Rotavirus – Number of Vaccinated Infants
    10.13    Varicella – Total Number of Vaccinated People

    10.13.1    Varicella – Number of Vaccinated Adults
    10.13.2    Varicella – Number of Vaccinated Infants


    11.    Country – Global Vaccine Market

    11.1    North America

    11.1.1    United States
    11.1.2    Canada

    11.2    Europe

    11.2.1    United Kingdom
    11.2.2    Germany
    11.2.3    France
    11.2.4    Russia
    11.2.5    Italy
    11.2.6    Spain
    11.2.7    Switzerland

    11.3    Asia Pacific

    11.3.1    India
    11.3.2    China
    11.3.3    Japan
    11.3.4    Australia
    11.3.5    South Korea

    11.4    Latin America

    11.4.1    Mexico
    11.4.2    Brazil
    11.4.3    Argentina

    11.5    Middle East & Africa

    11.5.1    Saudi Arabia
    11.5.2    UAE
    11.5.3    South Africa

    11.6    Rest of the World


    12.    Porter’s Five Forces

    12.1    Bargaining Power of Buyers
    12.2    Bargaining Power of Suppliers
    12.3    Degree of Competition
    12.4    Threat of New Entrants
    12.5    Threat of Substitutes


    13.    SWOT Analysis

    13.1    Strengths
    13.2    Weaknesses
    13.3    Opportunities
    13.4    Threats


    14.    Vaccines Key Players Sales

    14.1    GlaxoSmithKline plc.

    14.1.1    Overview
    14.1.2    Recent Development
    14.1.3    Financial Insights

    14.2    Astrazeneca plc

    14.2.1    Overview
    14.2.2    Recent Development
    14.2.3    Financial Insights

    14.3    Sanofi Pasteur

    14.3.1    Overview
    14.3.2    Recent Development
    14.3.3    Financial Insights

    14.4    Pfizer, Inc.

    14.4.1    Overview
    14.4.2    Recent Development
    14.4.3    Financial Insights

    14.5    CSL Limited sales

    14.5.1    Overview
    14.5.2    Recent Development
    14.5.3    Financial Insights


    List of Figures:

    Figure-01:    Global – Vaccines Market (Million US$), 2018 – 2022
    Figure-02:    Global – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-03:    Global – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-04:    Global – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-05:    Global – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-06:    Global – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-07:    Global – Vaccinated People Volume (Million), 2018 – 2022
    Figure-08:    Global – Forecast for Vaccinated People Volume (Million), 2023 – 2028
    Figure-09:    Global – Adult Vaccinated People Volume (Million), 2018 – 2022
    Figure-10:    Global – Forecast for Adult Vaccinated People Volume (Million), 2023 – 2028
    Figure-11:    Global – Pediatric (Infant) Vaccinated People Volume (Million), 2018 – 2022
    Figure-12:    Global – Forecast for Pediatric (Infant) Vaccinated People Volume (Million), 2023 – 2028
    Figure-13:    Influenza – Total Vaccines Market (Million US$), 2018 – 2022
    Figure-14:    Influenza – Forecast for Total Vaccines Market (Million US$), 2023 – 2028
    Figure-15:    Influenza – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-16:    Influenza – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-17:    Influenza – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-18:    Influenza – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-19:    Cervical Cancer (HPV) – Vaccines Market (Million US$), 2018 – 2022
    Figure-20:    Cervical Cancer (HPV) – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-21:    Zoster (Shingles) – Vaccines Market (Million US$), 2018 – 2022
    Figure-22:    Zoster (Shingles) – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-23:    MMR – Total Vaccines Market (Million US$), 2018 – 2022
    Figure-24:    MMR – Forecast for Total Vaccines Market (Million US$), 2023 – 2028
    Figure-25:    MMR – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-26:    MMR – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-27:    MMR – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-28:    MMR – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-29:    Pneumococcal – Total Vaccines Market (Million US$), 2018 – 2022
    Figure-30:    Pneumococcal – Forecast for Total Vaccines Market (Million US$), 2023 – 2028
    Figure-31:    Pneumococcal – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-32:    Pneumococcal – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-33:    Pneumococcal – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-34:    Pneumococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-35:    Meningococcal – Total Vaccines Market (Million US$), 2018 – 2022
    Figure-36:    Meningococcal – Forecast for Total Vaccines Market (Million US$), 2023 – 2028
    Figure-37:    Meningococcal – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-38:    Meningococcal – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-39:    Meningococcal – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-40:    Meningococcal – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-41:    Hepatitis – Total Vaccines Market (Million US$), 2018 – 2022
    Figure-42:    Hepatitis – Forecast for Total Vaccines Market (Million US$), 2023 – 2028
    Figure-43:    Hepatitis – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-44:    Hepatitis – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-45:    Hepatitis – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-46:    Hepatitis – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-47:    TdaP and DTaP – Total Vaccines Market (Million US$), 2018 – 2022
    Figure-48:    TdaP and DTaP – Forecast for Total Vaccines Market (Million US$), 2023 – 2028
    Figure-49:    TdaP – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-50:    TdaP – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-51:    DTaP – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-52:    DTaP – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-53:    Travel and Miscellaneous – Vaccines Market (Million US$), 2018 – 2022
    Figure-54:    Travel and Miscellaneous – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-55:    Haemophilus Influenzae Type B (HIB) – Vaccines Market (Million US$), 2018 – 2022
    Figure-56:    Haemophilus Influenzae Type B (HIB) – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-57:    Combos (Combination) – Vaccines Market (Million US$), 2018 – 2022
    Figure-58:    Combos (Combination) – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-59:    Polio – Vaccines Market (Million US$), 2018 – 2022
    Figure-60:    Polio – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-61:    Rotavirus – Vaccines Market (Million US$), 2018 – 2022
    Figure-62:    Rotavirus – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-63:    Varicella – Vaccines Market (Million US$), 2018 – 2022
    Figure-64:    Varicella – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-65:    Varicella – Adult Vaccines Market (Million US$), 2018 – 2022
    Figure-66:    Varicella – Forecast for Adult Vaccines Market (Million US$), 2023 – 2028
    Figure-67:    Varicella – Pediatric (Infant) Vaccines Market (Million US$), 2018 – 2022
    Figure-68:    Varicella – Forecast for Pediatric (Infant) Vaccines Market (Million US$), 2023 – 2028
    Figure-69:    Influenza – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-70:    Influenza – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-71:    Influenza – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-72:    Influenza – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-73:    Influenza – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-74:    Influenza – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-75:    Cervical Cancer (HPV) – Number of Vaccinated People (Million), 2018 – 2022
    Figure-76:    Cervical Cancer (HPV) – Forecast for Number of Vaccinated People (Million), 2023 – 2028
    Figure-77:    Zoster (Shingles) – Number of Vaccinated People (Million), 2018 – 2022
    Figure-78:    Zoster (Shingles) – Forecast for Number of Vaccinated People (Million), 2023 – 2028
    Figure-79:    MMR – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-80:    MMR – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-81:    MMR – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-82:    MMR – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-83:    MMR – Number of Vaccinated Infants (Pediatric) (Million), 2018 – 2022
    Figure-84:    MMR – Forecast for Number of Vaccinated Infants (Pediatric) (Million), 2023 – 2028
    Figure-85:    Pneumococcal – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-86:    Pneumococcal – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-87:    Pneumococcal – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-88:    Pneumococcal – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-89:    Pneumococcal – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-90:    Pneumococcal – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-91:    Meningococcal – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-92:    Meningococcal – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-93:    Meningococcal – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-94:    Meningococcal – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-95:    Meningococcal – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-96:    Meningococcal – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-97:    Hepatitis – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-98:    Hepatitis – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-99:    Hepatitis – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-100:    Hepatitis – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-101:    Hepatitis – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-102:    Hepatitis – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-103:    TdaP and DTaP – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-104:    TdaP and DTaP – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-105:    TdaP – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-106:    TdaP – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-107:    DTaP – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-108:    DTaP – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-109:    Hib (Haemophilus Influenzae Type B) – Number of Vaaccinated Infants (Million), 2018 – 2022
    Figure-110:    Hib (Haemophilus Influenzae Type B) – Forecast for Number of Vaaccinated Infants (Million), 2023 – 2028
    Figure-111:    Combos (Combination Vaccines) – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-112:    Combos (Combination Vaccines) – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-113:    Polio – Number of Infants Immunized and Forecast (Million), 2018 – 2022
    Figure-114:    Polio – Forecast for Number of Infants Immunized and Forecast (Million), 2023 – 2028
    Figure-115:    Rotavirus – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-116:    Rotavirus – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-117:    Varicella – Total Number of Vaccinated People (Million), 2018 – 2022
    Figure-118:    Varicella – Forecast for Total Number of Vaccinated People (Million), 2023 – 2028
    Figure-119:    Varicella – Number of Vaccinated Adults (Million), 2018 – 2022
    Figure-120:    Varicella – Forecast for Number of Vaccinated Adults (Million), 2023 – 2028
    Figure-121:    Varicella – Number of Vaccinated Infants (Million), 2018 – 2022
    Figure-122:    Varicella – Forecast for Number of Vaccinated Infants (Million), 2023 – 2028
    Figure-123:    United States – Vaccines Market (Million US$), 2018 – 2022
    Figure-124:    United States – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-125:    Canada – Vaccines Market (Million US$), 2018 – 2022
    Figure-126:    Canada – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-127:    United Kingdom – Vaccines Market (Million US$), 2018 – 2022
    Figure-128:    United Kingdom – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-129:    Germany – Vaccines Market (Million US$), 2018 – 2022
    Figure-130:    Germany – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-131:    France – Vaccines Market (Million US$), 2018 – 2022
    Figure-132:    France – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-133:    Russia – Vaccines Market (Million US$), 2018 – 2022
    Figure-134:    Russia – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-135:    Italy – Vaccines Market (Million US$), 2018 – 2022
    Figure-136:    Italy – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-137:    Spain – Vaccines Market (Million US$), 2018 – 2022
    Figure-138:    Spain – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-139:    Switzerland – Vaccines Market (Million US$), 2018 – 2022
    Figure-140:    Switzerland – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-141:    India – Vaccines Market (Million US$), 2018 – 2022
    Figure-142:    India – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-143:    China – Vaccines Market (Million US$), 2018 – 2022
    Figure-144:    China – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-145:    Japan – Vaccines Market (Million US$), 2018 – 2022
    Figure-146:    Japan – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-147:    Australia – Vaccines Market (Million US$), 2018 – 2022
    Figure-148:    Australia – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-149:    South Korea – Vaccines Market (Million US$), 2018 – 2022
    Figure-150:    South Korea – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-151:    Mexico – Vaccines Market (Million US$), 2018 – 2022
    Figure-152:    Mexico – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-153:    Brazil – Vaccines Market (Million US$), 2018 – 2022
    Figure-154:    Brazil – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-155:    Argentina – Vaccines Market (Million US$), 2018 – 2022
    Figure-156:    Argentina – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-157:    Saudi Arabia – Vaccines Market (Million US$), 2018 – 2022
    Figure-158:    Saudi Arabia – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-159:    UAE – Vaccines Market (Million US$), 2018 – 2022
    Figure-160:    UAE – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-161:    South Africa – Vaccines Market (Million US$), 2018 – 2022
    Figure-162:    South Africa – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-163:    Rest of the World – Vaccines Market (Million US$), 2018 – 2022
    Figure-164:    Rest of the World – Forecast for Vaccines Market (Million US$), 2023 – 2028
    Figure-165:    GlaxoSmithKline, plc. – Global Revenue (Billion US$), 2018 – 2022
    Figure-166:    GlaxoSmithKline, plc. – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-167:    Astrazeneca plc – Global Revenue (Million US$), 2018 – 2022
    Figure-168:    Astrazeneca plc – Forecast for Global Revenue (Million US$), 2023 – 2028
    Figure-169:    Sanofi Pasteur – Global Revenue (Billion US$), 2018 – 2022
    Figure-170:    Sanofi Pasteur – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-171:    Pfizer, Inc. – Global Revenue (Billion US$), 2018 – 2022
    Figure-172:    Pfizer, Inc. – Forecast for Global Revenue (Billion US$), 2023 – 2028
    Figure-173:    CSL Limited – Global Revenue (Billion US$), 2018 – 2022
    Figure-174:    CSL Limited – Forecast for Global Revenue (Billion US$), 2023 – 2028


    List of Tables:

    Table-01:    Global – Vaccines Market Share (Percent), 2018 – 2022
    Table-02:    Global – Forecast for Vaccines Market Share (Percent), 2023 – 2028
    Table-03:    Global – Vaccines Market Share by Country (Percent), 2018 – 2022
    Table-04:    Global – Forecast for Vaccines Market Share by Country (Percent), 2023 – 2028
    Table-05:    Global – Vaccinated People Share (Percent), 2018 – 2022
    Table-06:    Global – Forecast for Vaccinated People Share (Percent), 2023 – 2028
    Table-07:    Global – Adult Vs Pediatric (Infant) Vaccines Market Share (Percent), 2018 – 2022
    Table-08:    Global – Forecast for Adult Vs Pediatric (Infant) Vaccines Market Share (Percent), 2023 – 2028
    Table-09:    Global – Adult Vs Pediatric (Infant) Vaccines Number Share (Percent), 2018 – 2022
    Table-10:    Global – Forecast for Adult Vs Pediatric (Infant) Vaccines Number Share (Percent), 2023 – 2028

    • Description
      Price
    • Chapter 1 & 4     Pages : 4
      $200
    • Chapter 5     Pages : 4
      $300
    • Chapter 6     Pages : 4
      $300
    • Chapter 9     Pages : 42
      $1,000
    • Chapter 10     Pages : 40
      $1,000
    • Chapter 11.1     Pages : 4
      $200
    • Chapter 11.2     Pages : 14
      $500
    • Chapter 11.3     Pages : 10
      $400
    • Chapter 11.4     Pages : 6
      $300
    • Chapter 11.5 & 11.6     Pages : 8
      $300
    • Chapter 12     Pages : 5
      $200
    • Chapter 13     Pages : 4
      $200
    • Chapter 14.1     Pages : 5
      $150
    • Chapter 14.2     Pages : 5
      $150
    • Chapter 14.3     Pages : 5
      $150
    • Chapter 14.4     Pages : 5
      $150
    • Chapter 14.5     Pages : 5
      $150

    Related Reports